Astratus raises £385K seed round to accelerate rapid AMR testing

What's the deal? AstratusDealroom has a profile for this one. Try Dealroom →, a University of Reading spin-out developing rapid antimicrobial susceptibility testing, has raised £385,000 in a funding round backed by Henley Business AngelsDealroom has a profile for this one. Try Dealroom → (HBA) and Jenson VenturesDealroom has a profile for this one. Try Dealroom →. The company aims to replace slow, labour-intensive microbiology testing with faster, more scalable methods to improve antibiotic prescribing.

Why now? Antimicrobial resistance (AMR) is a mounting global crisis. Deaths linked to AMR are projected to reach 39 million by 2050 — roughly three every minute — with an estimated economic burden of $66B globally.

Current testing methods take two to seven days to deliver results, require trained microbiologists, and create major laboratory bottlenecks. More than 20% of antibiotic prescriptions issued to NHS patients are ineffective against the bacteria causing infection, while around 25% of tested samples show antibiotic-resistant bacteria.

What could go wrong? Scaling novel diagnostics in healthcare is notoriously difficult. Regulatory approvals, NHS procurement cycles, and the need to prove clinical validity against entrenched lab workflows all pose hurdles. At £385,000, the raise is modest — Astratus will likely need significantly more capital to bring a product to market and achieve meaningful adoption.

The signal: Henley Business Angels, classified as an investment fund on Dealroom, backing an early-growth university spin-out at a modest £385,000 reflects the reality of AMR diagnostics — a sector where the clinical urgency vastly outpaces the venture capital flowing in. With AMR's projected $66B global economic burden dwarfing current investment levels, Astratus's round underscores both the opportunity and the funding gap that still defines the space.

Read more: UK Business Angels Association